MigVax is developing an oral COVID-19 sub-unit vaccine. 

The MigVax approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx.

This method, based on the IBV vaccine, generates three kinds of immunological response:

1. mucosal immunity- IgA

2. Blood-based immunity-IgG

3. Cell-mediated immunity.

​

The MigVax vaccine is based on a vaccine developed for Infectious Bronchitis Virus which is a coronavirus that infects chickens.​